January 3, 2019 10:27 AM EST
R&D
Pharma

Af­ter blue­print­ing R&D hub, Ab­b­Vie dish­es out $105M for CD39 pact with Tizon­a's new CEO from Roche

Amber Tong

With the $10 bil­lion Ro­va-T pro­gram seem­ing­ly head­ed to­ward the cliff, Ab­b­Vie is turn­ing to an ear­ly-stage col­lab­o­ra­tion for a longer shot at can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times